Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00695955 · ClinicalTrials.gov registry record · Phase 3
One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 669
- Enrollment target
NCT00695955: Completed Phase 3 study, sponsored by Takeda.
NCT00695955 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 669 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00695955, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 669 participants
- Enrollment target
Study Summary
This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.
Primary Outcome
Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug.
Interventions
- DRUG Azilsartan medoxomil with or without add-on chlorthalidone
- DRUG Azilsartan medoxomil with or without add-on hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 669 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
What the finished NCT00695955 record still lists
NCT00695955 is an interventional study that assigns participants to a tested intervention. The registered 669 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 2 interventions - of which Azilsartan medoxomil with or without add-on chlorthalidone is the first listed.
NCT00695955 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00695955 about?
NCT00695955 is a clinical study titled "One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension". This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.
What is the current status of trial NCT00695955?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 669 participants. The study started on 2007-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00695955?
The interventions under investigation include: Azilsartan medoxomil with or without add-on chlorthalidone (DRUG), Azilsartan medoxomil with or without add-on hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00695955?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00695955's enrollment target sits among peer trials
669 547th of 2000 higher than 1,453 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02984761 · 670 participants · NA
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- NCT05727904 · 670 participants · Phase 3
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- NCT06223867 · 670 participants · NA
Efficacy, Effectiveness, and Implementation of Jaspr Health in Emergency Department- Part A
- NCT04155034 · 668 participants · Phase 3
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia